Wafik S. El‐Deiry

Small molecules targeting BRCA1-deficient cancer cells

The paper identifies small molecules that induce apoptosis in BRCA1-deficient cancer cells and links PPAR beta/delta inhibition to poor survival in breast cancer patients.

Efficacy of Tumor Treating Fields (TTFields) in triple negative breast cancer cells and synergy with PARP inhibitor talazoparib

This study shows TTFields increase p21 expression and induce cell death in TNBC cells, with enhanced effects when combined with talazoparib.

ONC201 in combination with ATR inhibitor ceralasertib exhibits potent synergy in ovarian cancer cells

This study shows that combining ONC201 with ATR inhibitor ceralasertib synergistically kills ovarian cancer cells by inducing apoptosis and reducing anti-apoptotic proteins.

Integrated stress response activation in combination PG3 and cisplatin-treated TP53-mutated head and neck squamous carcinoma cells induces potent apoptotic response

This study shows that combining PG3 with cisplatin enhances apoptosis in TP53-mutated HNSCC cells through ISR activation and ATF4 regulation.

Comparative Genomic and Epigenetic Landscape of Histone H3.3 G34R and K27M-Mutated Pediatric High-Grade Glioma Suggests Divergent Precision Oncology Strategies

This study compares genomic and epigenetic features of H3-G34R and H3-K27M mutated pediatric gliomas, identifying distinct molecular profiles and suggesting tailored therapeutic strategies.

Next-Generation Imipridones ONC206 and ONC212 Synergize with Lurbinectedin in Killing Pancreatic Ductal Adenocarcinoma Cells

This study shows that ONC206 and ONC212 synergize with lurbinectedin to kill pancreatic ductal adenocarcinoma cells with minimal toxicity to normal cells.

Synergistic cytotoxicity with Chk1/Chk2-inhibitor prexasertib in small cell lung cancer following lurbinectedin-induced G2/M-checkpoint activation

This paper shows that combining prexasertib with lurbinectedin synergistically kills small cell lung cancer cells by disrupting G2/M checkpoint responses.

Modulating populational variance of methyl-guanine methyl transferase expression through miR-181d degradation: a novel mechanism of temozolomide resistance

The paper shows that miR-181d degradation via a PNPT1-ATR feed-forward loop increases MGMT expression variance, leading to temozolomide resistance in glioblastoma cells.

Combination of Imipridone ONC201 or ONC206 with Temozolomide and Radiotherapy in triple ITR therapy reduces intracranial tumor burden and prolongs survival in an orthotopic wild-type IDH GBM mouse model

This paper shows that combining ONC201 or ONC206 with temozolomide and radiotherapy significantly extends survival in a GBM mouse model compared to single treatments.

TRAIL receptor agonist TLY012 in combination with PD-1 inhibition promotes tumor regression in an immune-competent mouse model of pancreatic ductal adenocarcinoma

This study shows that combining TLY012 with PD-1 inhibition reduces PDAC tumor growth in mice by enhancing proinflammatory cytokines and immune cell infiltration.

Neuroendocrine differentiation (ND) in sensitivity of neuroendocrine tumor (NET) cells to ONC201/TIC10 cancer therapeutic

This study shows that ONC201 is effective against prostate cancer and small cell lung carcinoma cells, regardless of neuroendocrine differentiation markers or BRN2 overexpression.

Tumor suppressor p73 transcriptionally regulates c-FLIP to impede its priming of extrinsic apoptosis while a switcher compound degrades c-FLIP protein

This study shows p73 upregulates c-FLIP to suppress extrinsic apoptosis, and a compound degrades c-FLIP to enhance p73's antitumor effects in p53-mutant cancers.

ITGB6 inhibition stimulates anti-tumor responses in immunocompetent mouse models of head & neck squamous cell carcinoma and pancreatic adenocarcinoma

This study shows that inhibiting ITGB6 enhances anti-tumor immune responses in mouse models of head and neck and pancreatic cancers, with potential for combination immunotherapy.

SARS-CoV-2 spike S2 subunit inhibits p53 activation of p21(WAF1), TRAIL Death Receptor DR5 and MDM2 proteins in cancer cells

This study shows that SARS-CoV-2 spike S2 subunit inhibits p53 activation of p21(WAF1), DR5, and MDM2 in cancer cells, potentially affecting tumorigenesis and chemotherapy response.

Neuroendocrine Prostate Cancer Drivers SOX2 and BRN2 Confer Differential Responses to Imipridones ONC201, ONC206, and ONC212 in Prostate Cancer Cell Lines

This study investigates whether neuroendocrine differentiation (NED) affects sensitivity to imipridones ONC201 and ONC206 in prostate cancer cell lines, finding differential responses based on SOX2 and BRN2 overexpression.

Synergistic combination therapy with ONC201 or ONC206, Enzalutamide and Darolutamide in preclinical studies of castration-resistant prostate cancer

This study shows that combining ONC201 with enzalutamide or darolutamide synergistically reduces mCRPC cell viability and PSA levels, with in vivo anti-tumor effects.